Name: Hematology Educational: Hematology Educational
Start: 2016-10-22T08:30
End: 2016-10-22T12:00
Location: Großer Saal

08:30 – 12:00

Room: Großer Saal

Hematology Educational Hematology Educational

Martin Dreyling
Anton Hagenbeek

08:30–08:35
Introduction
- Martin Dreyling
- Anton Hagenbeek
08:35–09:10
Chronic Lymphocytic Leukemia (CLL)
- Michael Hallek
09:10–09:45
Mantle Cell Lymphoma (MCL)
- Martin Dreyling
09:45–10:20
Aggressive Non-Hodgkin Lymphoma
- Wyndham Wilson
10:20–10:50

Coffee break
10:50–11:25
Follicular Lymphoma (FL)
- Anton Hagenbeek
11:25–12:00
Multiple Myeloma (MM)
- Christoph Scheid

09:00 – 10:30

Room: Isabellensaal

Workshop New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints

Richard Hoppe
Joachim Yahalom

Radiation eld reduction beyond ISRT? – options and concerns
- George Mikhaeel
Avoidance of organs at risk / dose-volume constraints – deep inspiration breath hold: techniques and daily monitoring
- David Hodgson
Avoidance of organs at risk / dose-volume constraints – dose / volume constrains for key organs at risk
- Berthe Aleman

09:00 – 10:30

Room: Kleiner Saal

Workshop Epidemiology and Registry Data

Magnus Björkholm
Nelson Spector

Welcome and short introduction
- Magnus Björkholm
- Nelson Spector
Experience from the international T cell project
- Massimo Federico
Registry studies on Hodgkin Lymphoma – the US experience
- Rahul Parikh
Registry-based studies on socio-economic impact on outcome in Hodgkin Lymphoma in Brazil
- Irene Biasoli
Registry-based studies on pregnancy in Hodgkin Lymphoma patients
- Caroline Weibull
Registry-based research – pros and cons – the statistician’s view
- Paul Dickman
General discussion

10:45 – 12:15

Room: Isabellensaal

Workshop Pathology and Pathogenesis

Andreas Rosenwald
Anke van den Berg

Risk and prognosis in Hodgkin Lymphoma and associations with an active, innate or anergic tumor immune response
- Ingrid Glimelius
NF-KB / IRF5 in Hodgkin Lymphoma
- Stephan Mathas
Noncoding RNAs and microRNA in Hodgkin Lymphoma
- Joost Kluiver

10:45 – 12:15

Room: Kleiner Saal

Workshop PET

Bruce Cheson
Martin Hutchings

Pretreatment stage or metabolic volume: which is better to direct treatment strategy?
- Michel Meignan
Response assessment in the era of checkpoint inhibitors
- Philippe Armand

12:45 – 13:45

Room: Großer Saal

Satellite Symposium (by Celgene GmbH) Recent Advances in the Treatment of Lymphoma

Andreas Engert

The FLASH project: establishing a novel surrogate endpoint in first-line FL
- Wolfgang Hiddemann
Update on clinical data of IMiDs® in the treatment of lymphoma
- Pier Luigi Zinzani

14:00 – 15:30

Room: Großer Saal

Workshop Biomarkers

Christian Steidl
Bastian von Tresckow

Methodological issues of circulating cell-free DNA detection in HL
- Peter Vandenberghe
Outcome prediction of aSCT using Hodgkin Lymphoma relapse biopsies
- Fong Chun Chan
Nanostring-based outcome prediction in HL patients treated with BEACOPP
- Andreas Rosenwald
Integration of IPS factors with gene expression for treatment outcome prediction
- Catherine Diefenbach
Biomarkers / companion diagnostics for checkpoint inhibition
- Stephen Ansell

14:00 – 15:30

Room: Kleiner Saal

Workshop Elderly Patients

Boris Böll
Jonathan Friedberg

US experience in elderly HL
- Andrew Evens
European experience in elderly HL
- Marc André
Geriatric assessment
- Ulrich Wedding
Trials on Brentuximab Vedotin and checkpoint inhibitors in elderly HL
- Jonathan Friedberg
Population based data on elderly HL
- Magnus Björkholm

14:00 – 15:30

Room: Isabellensaal

Workshop GHSG Workshop

Andreas Engert
Michael Fuchs

16:00 – 17:30

Room: Großer Saal

Workshop Genetics and Microenvironment

Ralf Küppers
Margaret Shipp

Molecular pathogenesis of NLPHL
- Sylvia Hartmann
The B cell receptor speci city of LP cells in NLPHL
- Lorenz Thurner
- Abstract Talk
Hodgkin cell-derived extracellular vesicles shape broblast activity
- Teresa Bösl
- Abstract Talk
The lymphoid cell speci c transcription factor ELF-1 is downregulated and deleted in classical Hodgkin lymphoma
- Maciej Giefing
- Abstract Talk
Tightly regulated FOXO3 expression is critical for the maintenance of cHL
- Clarissa Weitzer

16:00 – 17:30

Room: Isabellensaal

Workshop NLPHL

Joseph Connors
Andreas Engert

Update on classi cation of NLPHL and its distinction from TCRBCL and transformed DLBCL
- Nancy L. Harris
Latest GHSG data on NLPHL
- Dennis Eichenauer
Case studies of patients with “apparent” relapse of NLPHL
- Joseph Connors

16:00 – 17:30

Room: Kleiner Saal

Workshop Late Effects

Lena Specht
Flora van Leeuwen

Influence of radiotherapy and chemotherapy in modern Hodgkin Lymphoma treatment on risks of cardiovascular disease and second malignancy
- Lena Specht
Reducing cardiovascular risk in Hodgkin Lymphoma survivors – the SECURE trial
- John Radford
Phase 2 trial comparing the feasibility and efficacy of physical activity and multifactorial drug treatment in Hodgkin Lymphoma survivors
- Flora van Leeuwen

17:45 – 19:15

Room: Großer Saal

Satellite Symposium (by Novartis Pharma GmbH (Oncology)) Into the Future – New Treatment Options for Hematologic Malignancies

Peter Borchmann

17:45–17:50
Welcome
- Peter Borchmann
17:50–18:05
Midostaurin – a novel therapeutic approach for patients with FLT3-mutated AML
- Thomas Fischer
18:05–18:20
The concept of treatment-free remission in CML – results from current studies
- Alexander Kiani
18:20–18:35
Panobinostat for relapsed or refractory myeloma: pan-HDAC-inhibition with epigenetic e ects
- Andreas Günther
18:35–19:20
Advances in the treatment of hematologic malignancies: use of CAR T cells
- Peter Borchmann

Program: Saturday (22.10.2016)

08:30 – 12:00

Hematology Educational Hematology Educational

Introduction

Chronic Lymphocytic Leukemia (CLL)

Mantle Cell Lymphoma (MCL)

Aggressive Non-Hodgkin Lymphoma

Coffee break

Follicular Lymphoma (FL)

Multiple Myeloma (MM)

09:00 – 10:30

Workshop New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints

Radiation eld reduction beyond ISRT? – options and concerns

Avoidance of organs at risk / dose-volume constraints – deep inspiration breath hold: techniques and daily monitoring

Avoidance of organs at risk / dose-volume constraints – dose / volume constrains for key organs at risk

09:00 – 10:30

Workshop Epidemiology and Registry Data

Welcome and short introduction

Experience from the international T cell project

Registry studies on Hodgkin Lymphoma – the US experience

Registry-based studies on socio-economic impact on outcome in Hodgkin Lymphoma in Brazil

Registry-based studies on pregnancy in Hodgkin Lymphoma patients

Registry-based research – pros and cons – the statistician’s view

General discussion

10:45 – 12:15

Workshop Pathology and Pathogenesis

Risk and prognosis in Hodgkin Lymphoma and associations with an active, innate or anergic tumor immune response

NF-KB / IRF5 in Hodgkin Lymphoma

Noncoding RNAs and microRNA in Hodgkin Lymphoma

10:45 – 12:15

Workshop PET

Pretreatment stage or metabolic volume: which is better to direct treatment strategy?

Response assessment in the era of checkpoint inhibitors

12:45 – 13:45

Satellite Symposium (by Celgene GmbH) Recent Advances in the Treatment of Lymphoma

The FLASH project: establishing a novel surrogate endpoint in first-line FL

Update on clinical data of IMiDs® in the treatment of lymphoma

14:00 – 15:30

Workshop Biomarkers

Methodological issues of circulating cell-free DNA detection in HL

Outcome prediction of aSCT using Hodgkin Lymphoma relapse biopsies

Nanostring-based outcome prediction in HL patients treated with BEACOPP

Integration of IPS factors with gene expression for treatment outcome prediction

Biomarkers / companion diagnostics for checkpoint inhibition

14:00 – 15:30

Workshop Elderly Patients

US experience in elderly HL

European experience in elderly HL

Geriatric assessment

Trials on Brentuximab Vedotin and checkpoint inhibitors in elderly HL

Population based data on elderly HL

14:00 – 15:30

Workshop GHSG Workshop

16:00 – 17:30

Workshop Genetics and Microenvironment

Molecular pathogenesis of NLPHL

The B cell receptor speci city of LP cells in NLPHL

Hodgkin cell-derived extracellular vesicles shape broblast activity

The lymphoid cell speci c transcription factor ELF-1 is downregulated and deleted in classical Hodgkin lymphoma

Tightly regulated FOXO3 expression is critical for the maintenance of cHL

16:00 – 17:30

Workshop NLPHL

Update on classi cation of NLPHL and its distinction from TCRBCL and transformed DLBCL

Latest GHSG data on NLPHL

Case studies of patients with “apparent” relapse of NLPHL

16:00 – 17:30

Workshop Late Effects

Influence of radiotherapy and chemotherapy in modern Hodgkin Lymphoma treatment on risks of cardiovascular disease and second malignancy

Reducing cardiovascular risk in Hodgkin Lymphoma survivors – the SECURE trial

Phase 2 trial comparing the feasibility and efficacy of physical activity and multifactorial drug treatment in Hodgkin Lymphoma survivors

17:45 – 19:15

Satellite Symposium (by Novartis Pharma GmbH (Oncology)) Into the Future – New Treatment Options for Hematologic Malignancies

Welcome

Midostaurin – a novel therapeutic approach for patients with FLT3-mutated AML

The concept of treatment-free remission in CML – results from current studies

Panobinostat for relapsed or refractory myeloma: pan-HDAC-inhibition with epigenetic e ects

Advances in the treatment of hematologic malignancies: use of CAR T cells

Archive